The information Medicare plans to require providers submit to its own homegrown registry as a condition of administration of monoclonal antibody anti-amyloid treatments for Alzheimer’s should make it relatively easy for physicians to participate, but may ultimately make it harder for the US Centers for Medicare and Medicaid services to get critical answers about the effects of the treatments, experts told the Pink Sheet.
Key Takeaways
- CMS’s registry requirements for Alzheimer’s drugs seem designed to limit the burden on physicians and ease participation.
- The tradeoff is that CMS will likely have to rely on other registries and data collection to answer its own NCD questions
The Centers for Medicare and Medicaid released more details about the information it will require in its registry, as well as a portal where it will list any other registries it clears as fulfilling the Alzheimer’s National Coverage Determination requirements, on June 22
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
